cetuximab,bevacizumab,panitumumab
takeda,amgen,roche,eli lilly
[]
right vs left side . egfr inhibitors vs bev first debet continues. all started by post hoc secondary analysis done one year after original trial published. is it still valid ? may be not #ascogi23 #gi23 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists